Data to be presented as a late-breaking abstract at the 2025 European Society for Medical Oncology (ESMO) Breast Cancer Congress
Survey finds fear and misconceptions around hepatitis discourage testing, with more than half of respondents assuming they are not at risk
First-ever head-to-head trial comparing Xolair and oral immunotherapy (OIT)
Clinical mass spectrometry testing offers sensitivity and specificity, providing clinicians with additional diagnostic insights
The PATHWAY HER2 (4B5) test helps identify patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA
Roche’s Elecsys Amyloid Plasma Panel shows high accuracy in ruling out Alzheimer's, offering new hope for early and less invasive diagnostics
Roche obtains CE certification for VENTANA CLDN18 (43-14A) RxDx Assay to identify patients with gastric and gastroesophageal junction cancer eligible for targeted treatment with VYLOY
OCREVUS ZUNOVO has the potential to expand treatment options to centers without IV infrastructure or with IV constraints
The cobas c 703 and cobas ISE neo analytical units deliver greater efficiency and capacity to laboratories
Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization
The Roche Diagnostics Tina-quant Lp(a) assay measures lipoprotein (a) in a person’s bloodstream
Expanding access and screening options to help eliminate cervical cancer with one of the first HPV self-collection solutions in the US
Supporting earlier Alzheimer's disease diagnosis
The cobas Malaria test is the first FDA-approved molecular test to screen US blood donors for malaria
The test detects T-cell response, which may play an important role in determining if immune protection has been achieved
The VENTANA DP 600 is Roche’s new, high-capacity slide scanner that creates high-resolution, digital images of stained tissue samples that help to diagnose cancer and determine a patient’s treatment
The AVENIO Tumor Tissue Comprehensive Genomic Profiling Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science
The VENTANA PD-L1 (SP263) Assay helps determine which non-small cell lung cancer patients may benefit from treatment with Tecentriq immunotherapy based on the results of the Phase III IMpower010 study
The three new respiratory test panels on cobas 6800/8800 Systems in CE markets will help identify multiple pathogens with overlapping symptoms in patients
Using cancer biomarkers, the VENTANA MMR RxDx Panel helps determine which tumor patients may benefit from GSK immunotherapy
The drug aims to treat patients with myelodysplastic syndromes
The authorization enables emergency use of Actemra/RoActemra for the treatment of COVID-19 in hospitalized adult and pediatric patients
The test will be widely available to individuals through pharmacies and other locations in accordance with local guidelines and testing strategies
First commercial test will enable expedited coronavirus testing to meet urgent medical needs
